100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL

被引：30
|
作者：
Bronowicki, J-P [1 ]
Hezode, C. [2 ]
Bengtsson, L. [3 ]
Pol, S. [4 ]
Bourliere, M. [5 ]
Serfaty, L. [6 ]
de Ledinghen, V. [7 ]
Tran, A. [8 ]
Benhamou, Y. [9 ]
Grange, J-D [10 ]
Mathurin, P. [11 ]
Marcellin, P. [12 ]
Trepo, C. [13 ]
Zarski, J-P [14 ]
Seepersaud, S. [3 ]
Kelliher, K. [3 ]
Botfield, M. [3 ]
Pawlotsky, J-M [2 ]
机构：
[1] CHU Nancy, INSERM, U954, Nancy, France
[2] Hop Henri Mondor, F-94010 Creteil, France
[3] Vertex Pharmaceut Inc, Cambridge, MA USA
[4] Hop Cochin, F-75674 Paris, France
[5] Hop St Joseph, Marseille, France
[6] Hop St Antoine, F-75571 Paris, France
[7] CHU Bordeaux, Bordeaux, France
[8] CHU Nice, Nice, France
[9] Hop La Pitie Salpetriere, Paris, France
[10] Hop Tenon, F-75970 Paris, France
[11] CHU Lille, F-59037 Lille, France
[12] Hop Beaujon, Clichy, France
[13] CHU Lyon, Lyon, France
[14] CHU Grenoble, F-38043 Grenoble, France
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61106-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1094
引用
收藏
页码：S430 / S431
页数：2
相关论文
共 50 条
  • [11] Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
    Miyamura, Tatsuo
    Kanda, Tatsuo
    Nakamoto, Shingo
    Wu, Shuang
    Jiang, Xia
    Arai, Makoto
    Fujiwara, Keiichi
    Imazeki, Fumio
    Yokosuka, Osamu
    VIRUSES-BASEL, 2012, 4 (08): : 1264 - 1278
  • [12] TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
    Dusheiko, G. M.
    Jacobson, I. M.
    Catlett, I.
    George, S.
    Seepersaud, S.
    Ramachandran, R.
    Sussky, K.
    Kauffman, R. S.
    Botfield, M.
    GUT, 2011, 60 : A23 - A23
  • [13] LOW RATES OF SVR TO PEGINTERFERON PLUS RIBAVIRIN IN HCV GENOTYPE 1 IL28B RS12979860 CC CIRRHOTIC PATIENTS WITHOUT RAPID VIROLOGICAL RESPONSE
    Degasperi, E.
    Aghemo, A.
    Galmozzi, E.
    Valenti, L.
    Rumi, M. G.
    De Francesco, R.
    De Nicola, S.
    Soffredini, R.
    Colombo, M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S425 - S425
  • [14] PRE-TREATMENT IP-10 LEVELS AND IL28B GENOTYPE IN PREDICTION OF SVR IN PRIOR TREATMENT-EXPERIENCED GENOTYPE 1 HCV PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/ RIBAVIRIN IN THE REALIZE STUDY
    Vijgen, L.
    Talloen, W.
    Scholliers, A.
    Johansson, S.
    Tuefferd, M.
    De Meyer, S.
    Witek, J.
    Fanning, G.
    Picchio, G.
    Pol, S.
    Zeuzem, S.
    Aerssens, J.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S462 - S462
  • [15] Pre-treatment IP-10 levels and IL28B genotype as predictive markers for SVR in treatment-naive patients with genotype 1 HCV infection treated with telaprevir/peginterferon/ribavirin in the OPTIMIZE study
    Vijgen, Leen
    Dierynck, Inge
    Janssen, Katrien
    Talloen, Willem
    Gys, Luc
    Vanhoof, Greet
    Luo, Donghan
    De Meyer, Sandra
    Witek, James
    Aerssens, Jeroen
    HEPATOLOGY, 2013, 58 : 1096A - 1097A
  • [16] Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population
    Sghaier, Ikram
    Mouelhi, Leila
    Gazouani, Ezzedine
    Morel, Virginie
    Besma, Yacoubi Loueslati
    Brochot, Etienne
    JOURNAL OF CLINICAL VIROLOGY, 2015, 69 : 184 - 189
  • [17] THE IL28B CC GENOTYPE STRONGLY PREDICTS EARLY VIRAL KINETICS IN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON-RIBAVIRIN
    Rallon, Norma I.
    Naggie, Susanna
    Restrepo, Clara
    Goldstein, David B.
    McHutchison, John G.
    Soriano, Vincent
    Benito, Jose M.
    HEPATOLOGY, 2010, 52 (04) : 385A - 385A
  • [18] Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
    Jeong, Seok Hoo
    Jung, Young Kul
    Yang, Jae Won
    Park, Sang Jin
    Kim, Jong Woo
    Kwon, Oh Sang
    Kim, Yun Soo
    Choi, Duck Joo
    Kim, Ju Hyun
    CLINICAL AND MOLECULAR HEPATOLOGY, 2012, 18 (04) : 360 - 367
  • [19] TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IMPROVED RATES OF SUSTAINED VIROLOGIC RESPONSE (SVR) IN "DIFFICULT-TO-CURE" PATIENTS WITH CHRONIC HEPATITIS C (CHC): A POOLED ANALYSIS FROM THE PROVE1 AND PROVE2 TRIALS
    Everson, Gregory T.
    Dusheiko, Geoffrey M.
    Ferenci, Peter
    Alves, Katia
    Bengtsson, Leif
    McNair, Lindsay
    McHutchison, John G.
    Muir, Andrew
    Pawlotsky, Jeon-Michel
    Zeuzem, Stefan
    HEPATOLOGY, 2009, 50 (04) : 1025A - 1025A
  • [20] Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin
    Scherzer, Thomas-Matthias
    Hofer, Harald
    Staettermayer, Albert Friedrich
    Rutter, Karoline
    Beinhardt, Sandra
    Steindl-Munda, Petra
    Kerschner, Heidrun
    Kessler, Harald H.
    Ferenci, Peter
    JOURNAL OF HEPATOLOGY, 2011, 54 (05) : 866 - 871
12345